Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers.
Effects of pregabalin on smoking behavior, withdrawal symptoms, and cognitive performance in smokers.
复制标题
DOI：
10.1007/s00213-011-2507-x
复制
发表时间：
2012-04
影响因子：
3.4
通讯作者：
Sofuoglu, Mehmet
中科院分区：
文献类型：
--
作者：
Herman, Aryeh I;Waters, Andrew J;McKee, Sherry A;Sofuoglu, Mehmet
在临床前和临床研究中，增强GABA神经传递的药物会减弱尼古丁奖励。普瑞巴林是一种GABA类似物，可能与大脑谷氨酸和GABA神经传递相互作用。这项研究的目的是确定普瑞巴林对吸烟行为、尼古丁戒断、对香烟的渴望和认知能力的影响。24名吸烟者参加了一项门诊双盲、安慰剂对照、交叉研究。受试者接受为期4天的普瑞巴林(300毫克/天)或安慰剂的治疗，然后在冲洗期结束后，交叉进行4天的另一治疗。在每个治疗周期中，从第一天午夜开始，参与者被要求戒烟，直到第四天的实验阶段。在实验阶段中，获得了即兴吸烟行为、戒烟、对香烟的渴望和认知表现的测量。与安慰剂相比，普瑞巴林治疗并没有减少治疗前3天或临时吸烟期的吸烟行为。普瑞巴林治疗减轻了戒烟者的一些戒烟症状，包括焦虑、易怒和沮丧。普瑞巴林治疗也减弱了对吸烟反应的主观喜欢的评分。在普瑞巴林治疗下，吸烟者在持续的注意力任务中犯了更多的错误。这些发现为普瑞巴林作为尼古丁成瘾的治疗方法提供了有限的支持。
In preclinical and clinical studies, medications enhancing the GABA neurotransmission attenuate nicotine reward. Pregabalin, a GABA analogue, presumably interacts with brain glutamate and GABA neurotransmission. The goal of this study was to determine pregabalin's effects on smoking behavior, nicotine withdrawal, craving for cigarettes, and cognitive performance. Twenty-four smokers participated in an outpatient double-blind, placebo-controlled, crossover study. Subjects had a 4-day treatment period with either pregabalin (300 mg/day) or placebo and following a washout period were then crossed over for 4 days to the other treatment. In each treatment period, starting at midnight of Day 1, participants were asked to stop smoking until the experimental session on Day 4. During the experimental session measures of ad lib smoking behavior, tobacco withdrawal, craving for cigarettes, and cognitive performance were obtained. Pregabalin treatment, compared to placebo, did not reduce the smoking behavior during the first 3 days of treatment or during ad lib smoking period. Pregabalin treatment attenuated some tobacco withdrawal symptoms including ratings of anxious, irritable, and frustrated in abstinent smokers. Pregabalin treatment also attenuated the subjective ratings of “liking” in response to smoking. Under pregabalin treatment, smokers made more errors in a sustained attention task. These findings provide limited support for pregabalin as a treatment for nicotine addiction.